The purpose of this study is to investigate the safety and tolerability of MK0974 in the long-term treatment of acute migraine...
Date First Received: February 28, 2007
Last Updated: August 17, 2007
Verified by: Merck, August 2007
Clinical Trial Phase: Phase 3 | Start Date: March 2007
Overall Status: Active, not recruiting
Estimated Enrollment: 900
Brief Summary
Official Title: “Long-Term Intermittent Treatment of Acute Migraine With MK0974”
Condition Keyword(s):
The purpose of this study is to investigate the safety and tolerability of MK0974 in the long-term treatment of acute migraine.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: MK0974 / Duration of Treatment: 1 Years
- Drug: Comparator: rizatriptan benzoate / Duration of Treatment: 1 Years
Outcome Measures for this Clinical Trial
Primary Measures
- Adverse experiences, laboratory values, ECGs, and vital signs
- Time Frame: During the study
- Time Frame: During the study
Secondary Measures
- Pain freedom
- Time Frame: 2 hours post-dose
- Time Frame: 2 hours post-dose
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patient has at least 1 year history of migraine (with or without aura)
- Females of child bearing potential must use acceptable contraception throughout trial
- Patient is in general good health based on screening assessment
Exclusion Criteria:
- Patient is pregnant/breast-feeding (or is a female expecting to conceive during study period)
- Patient has history or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or HIV disease
- Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)
- Patient has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption
- Patient has a history of cancer within the last 5 years
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Merck
Overall Clinical Trial Officials and Contacts
Medical Monitor Study Director Merck
Additional Information
Information obtained from ClinicalTrials.gov on August 29, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00443209
Study ID Number: 2006_524
ClinicalTrials.gov Identifier: NCT00443209
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.